Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Deciphera Pharmaceuticals (NASDAQ: DCPH) announced its participation in fireside chats at two upcoming investor conferences. The first event, Guggenheim Healthcare Talks Oncology Day, will be held on February 9, 2023, at 10:45 AM ET in New York, NY. The second, SVB Securities Global Biopharma Conference, is scheduled for February 15, 2023, at 3:00 PM ET and will be virtual. Both events will be webcast live, with recordings available for 90 days afterward. Deciphera is focused on developing innovative cancer treatments, including QINLOCK®, approved in multiple countries for fourth-line GIST treatment.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:

• Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023 at 10:45 AM ET in New York, NY
• SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 3:00 PM ET (virtual)

A live webcast of both events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of both webcasts will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK^® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Israel, New Zealand, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005015/en/

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902



Media:

David Rosen

Argot Partners

david.rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

When will Deciphera Pharmaceuticals participate in the Guggenheim Healthcare Talks Oncology Day?

Deciphera Pharmaceuticals will participate in the Guggenheim Healthcare Talks Oncology Day on February 9, 2023, at 10:45 AM ET.

What is the date and time for the SVB Securities Global Biopharma Conference?

The SVB Securities Global Biopharma Conference will take place on February 15, 2023, at 3:00 PM ET.

Where can I watch the live webcasts of Deciphera's investor conference events?

Live webcasts of Deciphera's investor conference events can be viewed on the 'Events and Presentations' page in the 'Investors' section of their website.

What is QINLOCK® and its significance for Deciphera Pharmaceuticals?

QINLOCK® is Deciphera's switch-control inhibitor approved for the treatment of fourth-line GIST, enhancing the company's portfolio of innovative cancer therapies.

In which countries is QINLOCK® approved?

QINLOCK® is approved in Australia, Canada, China, the European Union, Hong Kong, Israel, New Zealand, Switzerland, Taiwan, the United Kingdom, and the United States.